During the last 20 years, the rules and regulations regarding pain, opioid prescribing and opioid use disorder have changed significantly. Attendees will be taught the latest and most up-to-date information on DEA’s authority and background, licensing, registration, drug diversion, telemedicine, medication assistance treatment, nationwide opioid prescribing guidelines and case studies, along with learning risk mitigation strategies and best practices that will safeguard their practices. The instructor is a former DEA Special Agent with over 30 years of public service with real life prescription opioid experience. | 1.50 credits CE/CME category 1 credits (1.00 Pharmacology) | $40

Healthcare providers in the United States are well positioned to recognize substance use in their patients. Providers are also key in taking steps to address issues of substance use before it escalates to abuse. Unfortunately, substance use and abuse in adolescents remains undertreated in the United States. Early intervention in adolescents with substance use/abuse disorders is crucial in averting economic cost in this population group. This presentation will review treatment options for adolescents who present with various types of substance use disorders. Motivators for seeking treatment as well as gender and ethnicity will also be addressed. Barriers to treatment will also be discussed. | 1.50 credits CE/CME category 1 credits (1.50 Pharmacology) | $40

This presentation offers a comprehensive exploration of Opioid Use Disorder (OUD), equipping nurse practitioners and healthcare professionals with essential tools to address this growing crisis. Attendees will gain a deeper understanding of the assessment and diagnosis of OUD using DSM-5-TR criteria, along with strategies for managing opioid intoxication, overdose, and withdrawal. The session will also cover evidence-based treatment options, both pharmacological and non-pharmacological, emphasizing a patient-centered approach. With a focus on practical application and current statistics, this engaging and informative talk will prepare participants to effectively recognize and treat OUD, ultimately improving patient outcomes. | 1.50 CE/CME category 1 credits (1.50 Pharmacology) | $40

In response to the public health crisis of opioid abuse and overdose, the US Food & Drug Administration issued a Risk Evaluation and Mitigation Strategy (REMS). The REMS is part of a larger federal effort to reduce risks associated with the prescribing of long-term opioid therapy. With this national response, has come a recognition that improved knowledge of opioid safety is an essential clinical practice competency for all prescribers of opioids. This program discusses pain from a contextual perspective, patient selection and assessment of risk associated with opioid use for long-term management of chronic pain, as well as the use of opioids in the acute care setting and transition of care from the acute care setting into the community. The current 2022 CDC guidelines will be discussed. Case studies will be presented to build skills of improved recognition of opioid use disorder and decision making as to when patients should be weaned off of chronic opioids. | 1.5 CE/CME category 1 credits (1.50 Pharmacology) | $40

You have heard about cannabis, you know a little bit of the differences between THC and CBD, and you have a vague grasp on the endocannabinoid system, now your patient wants to try medicinal cannabis. What are the BASICS that you need to know? Is this you, “I am a busy clinician, and I have 15, maybe 20 minutes to learn all that I need to know about cannabis.”? This updated lecture will provide the busy clinician with the basics they need to knowledgably discuss medical cannabis and provide patients with the essentials to move forward safely. | 1.5 CE/CME category 1 credits (1.50 Pharmacology) | $40